Omega-3 carboxylic acids - AstraZeneca

Drug Profile

Omega-3 carboxylic acids - AstraZeneca

Alternative Names: AZD 0585; D-5884; DHA/EPA - AstraZeneca; Docosahexaenoic acid/eicosapentaenoic acid - AstraZeneca; Eicosapentaenoic acid/docosahexaenoic acid - AstraZeneca; EPA/DHA - AstraZeneca; Epanova; Omefas; Purepa

Latest Information Update: 06 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tillotts Pharma
  • Developer AstraZeneca; Cleveland Clinic; Tillotts Pharma
  • Class Antihyperlipidaemics; Carboxylic acids; Docosahexaenoic acids; Eicosanoids; Omega 3 fatty acids; Omega-6 fatty acids
  • Mechanism of Action Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Hypertriglyceridaemia
  • Phase II Non-alcoholic fatty liver disease
  • Research Cardiovascular disorders
  • Discontinued Crohn's disease

Most Recent Events

  • 27 Jun 2018 AstraZeneca completes a phase I trial for Healthy volunteers in China (NCT03574142)
  • 04 Jun 2018 AstraZeneca initiates a phase I trial for Healthy volunteers in China (NCT03574142)
  • 27 Jul 2017 Omega-3 carboxylic acids is still Registered (not yet launched) for Hypertriglyceridaemia in USA (AstraZeneca pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top